Search

Your search keyword '"Lin, Sheng‐Hao"' showing total 221 results
Start Over Author "Lin, Sheng‐Hao"
221 results on '"Lin, Sheng‐Hao"'

1. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor[FIGURE DASH]Resistant, EGFR–Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

Author

Yang, James Chih-Hsin, Lee, Dae Ho, Lee, Jong-Seok, Fan, Yun, de Marinis, Filippo, Iwama, Eiji, Inoue, Takako, Rodríguez-Cid, Jerónimo, Zhang, Li, Yang, Cheng-Ta, de la Mora Jimenez, Emmanuel, Zhou, Jianying, Pérol, Maurice, Lee, Ki Hyeong, Vicente, David, Ichihara, Eiki, Riely, Gregory J., Luo, Yiwen, Chirovsky, Diana, Pietanza, M. Catherine, Bhagwati, Niyati, Lu, Shun, Joseph Boyer, Michael, Hui, Rina, Wong, Mark, Mant, Andrew, Parente, Phillip, John, Thomas, Parakh, Sagun, Castro, Gilberto, Jr, Werutsky, Gustavo, de Azevedo, Sergio Jobim, Andre Franke, Fabio, De Almeida Rego, Joilda Batista, Martins De Marchi, Pedro Rafael, Dix Junqueira, Gustavo, Maris Peria, Fernanda, Brust, Leandro, Cheema, Parneet, Doherty, Mark, Parmar, Ambika, Menjak, Ines B., Leighl, Natasha B., Agulnik, Jason, Lu, Shun, Han, Zhigang, Cui, Jiuwei, Zhang, Li, Cheng, Ying, Chen, Gongyan, Zhang, Helong, Yao, Yu, Hu, Chengping, Wang, Qiming, Zhang, Xin, Zhang, Yong, Zhou, Jianying, Ying, Kejing, Fan, Yun, Wang, Yan, Wang, Ziping, Feng, Jifeng, Du, YingYing, Wu, Lin, Huang, Cheng, Zhou, Xiangdong, Perol, Maurice, Domont, Julien, Lamour, Corinne, Dutilh, Julien, Oulkhouir, Youssef, Westeel, Virginie, Carmier, Delphine, Coudert, Bruno, Lagrange, Aurelie, Spaeth, Dominique, Ropert, Stanislas, Christoph, Daniel C., Kern, Jens, Kopp, Hans-Georg, Griesinger, Frank, Wiewrodt, Rainer, Wermke, Martin, Wesseler, Claas, Mueller, Annette, Vogel, Gunther, Lee, Victor, James Ho, Chung Man, Oscar Chan, Siu Hong, Hung Lo, Sing, Jonathan Nyaw, Shi Feng, Jacky Li, Yu Chung, Bar, Jair, Gottfried, Maya, Dudnik, Julia, Zer, Alona, Moskovitz, Mor, Wollner, Mirjana, Rotem, Ofer, Shamai, Sivan, Asna, Noam, Kamel, Mhameed, Novello, Silvia, Di Costanzo, Francesco, Doni, Laura, Mazzoni, Francesca, Ferrau, Francesco, de Marinis, Filippo, Tonini, Giuseppe, Galetta, Domenico, Piantedosi, Francovito, Vitiello, Fabiana, Kirita, Keisuke, Yoh, Kiyotaka, Takahashi, Toshiaki, Ohe, Yuichiro, Hattori, Yoshihiro, Okamoto, Isamu, Kurata, Takayasu, Yoshioka, Hiroshige, Saka, Hideo, Oki, Masahide, Kato, Terufumi, Tanaka, Hiroshi, Kumagai, Toru, Inoue, Takako, Hida, Toyoaki, Horio, Yoshitsugu, Teraoka, Shunsuke, Ichihara, Eiki, Kishi, Kazuma, Takaya, Hisashi, Takai, Daiya, Kozuki, Toshiyuki, Kasahara, Kazuo, Tambo, Yuichi, Hosomi, Yukio, Kondo, Masashi, Ichiki, Masao, Takeoka, Hiroaki, de la Mora Jimenez, Emmanuel, Hernandez, Carlos Alberto, Rodriguez Cid, Jeronimo Rafael, Rodriguez, Oscar Gerardo Arrieta, Han, Ji-Youn, Min, Young Joo, Kim, Dong-Wan, Park, Keunchil, Lee, Se-Hoon, Lee, Ki Hyeong, Lee, Jong-Seok, Kang, Jin Hyoung, Lee, Dae Ho, Cho, Eun Kyung, Carcereny, Enric, Lopez, Pilar Garrido, Tarruella, Margarita Majem, Rodriguez, Luis Paz-Ares, Vicente Baz, David, Font, Enriqueta Felip, Cobo-Dols, Manuel, Ekman, Simon, Bergman, Bengt, Ohman, Ronny, Vikstrom, Anders, Yang, Chih-Hsin, Chiu, Chao-Hua, Huang, Hsu-Ching, Yang, Cheng-Ta, Su, Jian, Chang, Gee-Chen, Yang, Tsung-Ying, Hsia, Te-Chun, Su, Wu-Chou, Wu, Shang-Yin, Wang, Chin-Chou, Lee, Kang-Yun, Lin, Sheng-Hao, Lin, Chih-Bin, Lee, Jih-Hsiang, Huang, Chun-Yao, Ahmed, Samreen, Newsom-Davis, Thomas, Baijal, Shobhit, Brock, Juliet, Zaki, Kam, Shamash, Jonathan, Papadatos-Pastos, Dionysis, Jain, Pooja, Jane Mackean, Melanie, Kendall, Stephan DiSean, Anderson, Ian, Costin, Dan, Hall, Richard, Campbell, Nicholas, Khan, Saad, Dowell, Jonathan, Mashru, Sandeep, Menon, Smitha, Raza, Ahmad, Ge, Li, Riely, Gregory J., Seetharamu, Nagashree, Stampleman, Laura, Subramanian, Janakiraman, Wender, Donald B., Natale, Ronald B., Zhu, Viola, Ignatius Ou, Sai-Hong, Sanborn, Rachel, and Evangelist, Makenzi C.

Published
2024
Full Text
View/download PDF

9. VELOCITY-Lung substudy-03: A phase 2 study of neoadjuvant domvanalimab (dom)+zimberelimab (zim)+chemotherapy (chemo) or zim+chemo followed by adjuvant dom+zim or zim in patients with resectable stage II-III non-small cell lung cancer (NSCLC).

Author

Sadiq, Ahad Ali, primary, Shamai, Sivan, additional, Lin, Sheng-Hao, additional, Han, Ji-Youn, additional, Baijal, Shobhit, additional, Yazici, Ozan, additional, Barrios, Carlos H., additional, Zhang, Jie, additional, Chen, Kun, additional, Kim, Young, additional, Park, Joseph, additional, Ahlers, Christoph Matthias, additional, and Peled, Nir, additional

Published
2024
Full Text
View/download PDF

10. Particulate matter of 2.5 μm or less in diameter disturbs the balance of TH17/regulatory T cells by targeting glutamate oxaloacetate transaminase 1 and hypoxia-inducible factor 1α in an asthma model

Author

Sun, Licheng, Fu, Jinrong, Lin, Sheng-Hao, Sun, Jin-Lyu, Xia, Li, Lin, Ching-Hsiung, Liu, Lijuan, Zhang, Caiyan, Yang, Lan, Xue, Ping, Wang, Xiang, Huang, Saihua, Han, Xiao, Chen, Hua-Ling, Huang, Ming-Shyan, Zhang, Xiaobo, Huang, Shau-Ku, and Zhou, Yufeng

Published
2020
Full Text
View/download PDF

16. Acupuncture for ventilator-dependent patients at a hospital-based respiratory care center: A pilot randomized clinical trial

Author

Chen, Jia-Ming, primary, Chiang, Wan-Li, additional, Ji, Bin-Chuan, additional, Jhang, Ruei-Jhe, additional, Chen, Pei-Hsin, additional, Li, Ya-Lun, additional, Chang, Che-Ju, additional, Huang, Sung-Yen, additional, Lee, Tsung-Chieh, additional, Chen, Chia-Yun, additional, Lin, Ching-Hsiung, additional, and Lin, Sheng-Hao, additional

Published
2023
Full Text
View/download PDF

18. Impulse oscillometry in patients with persistent post‐COVID‐19 symptoms: A retrospective study.

Author

Lu, Chun‐Yu, Lin, Sheng‐Hao, and Chen, Chun‐Min

Subjects
COVID-19 pandemic, COVID-19, SYMPTOMS, LUNG volume, AIRWAY resistance (Respiration), COUGH
Abstract

Introduction: Impaired lung function has been observed in patients following COVID‐19 infection, with studies reporting persistent lung volume and diffusing capacity impairments. Some studies have demonstrated significantly higher small airway resistance in COVID‐19 positive cases. This retrospective study aims to examine impulse oscillometry (IOS) data of patients with persistent symptoms after COVID‐19 infection, focusing on the relationship between time and symptoms. Material and Method: The study analyzed data from adult patients with persistent symptoms who underwent IOS testing within and after 84 days from the diagnosis date. Result: The results showed that patients within 84 days and those between 31 and 84 days had higher small airway resistance values, indicating peripheral airway disease. Patients with dyspnea exhibited higher IOS values compared to those with cough symptoms, suggesting more significant impairment in the peripheral airways. Conclusion: The study highlights the importance of using comprehensive diagnostic tools like IOS to assess respiratory impairments in post‐COVID‐19 patients, particularly in the small airways. Understanding the relationship between time and symptoms can provide valuable insights for the treatment of peripheral airway dysfunction in post‐COVID‐19 patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. The Prognostic Value of Positron Emission Tomography/Computed Tomography in Clinical Stage I Lung Cancer Patients: A Propensity-Match Analysis.

Author

Cheng, Ya-Fu, Huang, Jing-Yang, Lin, Ching-Hsiung, Lin, Sheng-Hao, and Wang, Bing-Yen

Subjects
POSITRON emission tomography, COMPUTED tomography, LUNG cancer, CANCER patients, PROGNOSIS
Abstract

Background: The application of positron emission tomography/computed tomography (PET/CT) helps provide accurate clinical staging for lung cancer patients. However, the effects and trends in early-stage lung cancer remain unclear. The aim of this study was to compare differences between clinical stage I lung cancer patients who received PET/CT for staging and those who did not. Methods: Data were obtained from the Taiwan Society of Cancer Registry. There were 6587 clinical stage I lung cancer patients between 2009 and 2014 analyzed in this study. We compared the characteristics of the PET/CT and no PET/CT groups. After propensity score matching, it resulted in both groups having 2649 patients. We measured the overall survival rates of all clinical stage I lung cancer patients and the overall survival rates of patients with PET/CT and without PET/CT. Results: The 1-, 3-, and 5-year survival rates of all clinical stage I lung cancer patients were 97.2%, 88.2%, and 79.0%, respectively. Patients with a larger tumor size tended to receive PET/CT for staging (stage Ib: 38.25% vs. 27.82%, p < 0.0001) and a larger resection (lobectomy: 74.62% vs. 66.61%, p < 0.0001). The 5-year survival rates were 79.8% in the PET/CT group and 78.2% in the no PET/CT group after propensity score matching (p = 0.6528). Conclusions: For clinical stage I lung cancer in Taiwan, patients with larger tumor sizes tend to have PET/CT for staging. Although PET/CT provided more precise clinical staging, these patients still received larger resections and had more pathological migration. However, there was no overall survival rate benefit after PET/CT. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Current Progress of COPD Early Detection: Key Points and Novel Strategies

Author

Lin,Ching-Hsiung, Cheng,Shih-Lung, Chen,Chiung-Zuei, Chen,Chia-Hung, Lin,Sheng-Hao, Wang,Hao-Chien, Lin,Ching-Hsiung, Cheng,Shih-Lung, Chen,Chiung-Zuei, Chen,Chia-Hung, Lin,Sheng-Hao, and Wang,Hao-Chien

Abstract

Ching-Hsiung Lin,1– 4,&ast; Shih-Lung Cheng,5,6 Chiung-Zuei Chen,7 Chia-Hung Chen,8 Sheng-Hao Lin,1 Hao-Chien Wang9,&ast; 1Division of Chest Medicine, Changhua Christian Hospital, Changhua, 500, Taiwan; 2Institute of Genomics and Bioinformatics, National Chung Hsing University, Taichung, 402, Taiwan; 3Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan; 4Department of Recreation and Holistic Wellness, MingDao University, Changhua, Taiwan; 5Department of Internal Medicine, Far Eastern Memorial Hospital, Taipei, 220, Taiwan; 6Department of Chemical Engineering and Materials Science, Yuan Ze University, Taoyuan, 320, Taiwan; 7Division of Pulmonary Medicine, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; 8Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, 404, Taiwan; 9Department of Internal Medicine, National Taiwan University Hospital, Taipei, 100, Taiwan&ast;These authors contributed equally to this workCorrespondence: Hao-Chien Wang, Department of Internal Medicine, National Taiwan University Hospital, Taipei, 100, Taiwan, Tel + 886 2 2322-0322, Fax + 886 2 2322-0322, Email haochienwang@gmail.com Ching-Hsiung Lin, Department of Internal Medicine, Division of Chest Medicine, Changhua Christian Hospital, 135 Nanhsiao Street, Changhua, 50006, Taiwan, Tel +886-4-7238595, Fax +886-4-7232942, Email 47822@cch.org.twAbstract: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide, with approximately 70% to 80% of adults with COPD being undiagnosed. Patients with undiagnosed COPD are at increased risk of poor outcomes and a worsened quality of life, making early detection a crucial strategy to mitigate the impact of COPD and reduce the burden on healthcare systems. In the past decade, increased interest has be

Published
2023

26. BTEX exposure and its body burden pose differential risks for asthma and its phenotypic clusters

Author

Hsu, Yuan‐Ting, primary, Wu, Chao‐Chien, additional, Wang, Chin‐Chou, additional, Chung, Wen‐Yu, additional, Sheu, Chau‐Chyun, additional, Yang, Yi‐Hsin, additional, Cheng, Ming‐Yen, additional, Lai, Ruay‐Sheng, additional, Leung, Sum‐Yee, additional, Lin, Chi‐Cheng, additional, Wei, Yu‐Feng, additional, Lin, Ching‐Hsiung, additional, Lin, Sheng‐Hao, additional, Hsu, Jeng‐Yuan, additional, Huang, Wei‐Chang, additional, Tseng, Chia‐Cheng, additional, Lai, Yung‐Fa, additional, Cheng, Meng‐Hsuan, additional, Chen, Huang‐Chi, additional, Yang, Chih‐Jen, additional, Su, Chian‐Heng, additional, Wang, Chien‐Jen, additional, Hsu, Shih‐Chang, additional, Hung, Chih‐Hsing, additional, Lee, Chon‐Lin, additional, Huang, Ming‐Shyan, additional, and Huang, Shau‐Ku, additional

Published
2023
Full Text
View/download PDF

30. Environmental risks and sphingolipid signatures in adult asthma and its phenotypic clusters: a multicentre study

Author

Wu, Chao-Chien, primary, Wang, Chin-Chou, additional, Chung, Wen-Yu, additional, Sheu, Chau-Chyun, additional, Yang, Yi-Hsin, additional, Cheng, Ming-Yen, additional, Lai, Ruay-Sheng, additional, Leung, Sum-Yee, additional, Lin, Chi-Cheng, additional, Wei, Yu-Feng, additional, Lin, Ching-Hsiung, additional, Lin, Sheng-Hao, additional, Hsu, Jeng-Yuan, additional, Huang, Wei-Chang, additional, Tseng, Chia-Cheng, additional, Lai, Yung-Fa, additional, Cheng, Meng-Hsuan, additional, Chen, Huang-Chi, additional, Yang, Chih-Jen, additional, Hsu, Shih-Chang, additional, Su, Chian-Heng, additional, Wang, Chien-Jen, additional, Liu, Huei-Ju, additional, Chen, Hua-Ling, additional, Hsu, Yuan-Ting, additional, Hung, Chih-Hsing, additional, Lee, Chon-Lin, additional, Huang, Ming-Shyan, additional, and Huang, Shau-Ku, additional

Published
2022
Full Text
View/download PDF

31. Safety and effectiveness of transdermal buprenorphine in cancer pain: An observational study in Taiwan (SOOTHE)

Author

Huang, Tai‐Lin, primary, Huang, Yen‐Min, additional, Hou, Min‐Mo, additional, Lu, Chang‐Hsien, additional, Chao, Tsu‐Yi, additional, Chiu, Tai‐Jan, additional, Chang, Yueh‐Shih, additional, Lin, Sheng‐Hao, additional, Lin, Ching‐Hsiung, additional, Chen, Yen‐Hao, additional, Wang, Cheng‐Hsu, additional, Chen, Jen‐Shi, additional, and Shen, Wen‐Chi, additional

Published
2022
Full Text
View/download PDF

33. Safety and effectiveness of transdermal buprenorphine in cancer pain: An observational study in Taiwan (SOOTHE).

Author

Huang, Tai‐Lin, Huang, Yen‐Min, Hou, Min‐Mo, Lu, Chang‐Hsien, Chao, Tsu‐Yi, Chiu, Tai‐Jan, Chang, Yueh‐Shih, Lin, Sheng‐Hao, Lin, Ching‐Hsiung, Chen, Yen‐Hao, Wang, Cheng‐Hsu, Chen, Jen‐Shi, and Shen, Wen‐Chi

Subjects
CANCER pain, BUPRENORPHINE, PAIN measurement, BRIEF Pain Inventory, ASIANS, SCIENTIFIC observation
Abstract

Aim: Buprenorphine is one of the strongest opioids used for the relief of cancer pain. This study aims to evaluate the real‐world clinical experiences of transdermal buprenorphine used in moderate to severe cancer pain in the Asian population. Methods: This is an open‐labeled, multicenter, 4‐week observational study. Stable cancer pain patients who decided to switch the previous opioid to transdermal buprenorphine will be enrolled in this study. The safety and effectiveness were observed and collected. Pain assessment was performed using a numerical rating scale by the investigators and the Brief Pain Inventory Short Form (BPI‐SF) by the patient. The safety profiles included concomitant medications and adverse events (AEs). Results: A total of 83 patients were enrolled in this study. The global pain scores in the BPI, as well as the four individual pain parameters (worst, least, average, and right now), showed a continued decrease (p <.05) from week 2 to week 4. Significant improvements were observed in normal work activities, relations with other people, sleep, enjoyment of life, and global BPI pain interference score on week 4. Pain assessments conducted by investigators demonstrated significant, continuous improvements during the study periods. In addition, transdermal buprenorphine demonstrated good safety/tolerability with limited drug‐related AEs in the Asian population with cancer pain. Conclusion: This study demonstrated that transdermal buprenorphine in the Asian population has good safety profiles and continued improvements in pain relief, sleep, and pain interferences. Transdermal buprenorphine can be an effective and convenient option as a transdermal opioid for patients with moderate to severe cancer pain in Taiwan. (NCT Number: NCT04315831) [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

34. Diverse clinical outcomes for the EGFR‑mutated and ALK‑rearranged advanced non‑squamous non‑small cell lung cancer.

Author

Lin, Chun-Wei, Huang, Kuo-Yang, Lin, Ching-Hsiung, Hou, Ming-Hon, and Lin, Sheng-Hao

Subjects
NON-small-cell lung carcinoma, PROTEIN-tyrosine kinase inhibitors, EPIDERMAL growth factor receptors, OVERALL survival, PROGNOSIS
Abstract

EGFR and ALK are key driver mutations in non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors are recommended as the first-line treatment for advanced NSCLC with driving oncogenes because they have fewer side effects and provide better disease control than chemotherapy. The present retrospective analysis aimed to investigate how altered driver genes impact cancer outcomes and clinical presentation. A total of 628 patients with advanced-stage NSCLC and documented EGFR and ALK mutations were enrolled at Changhua Christian Hospital in Taiwan between August 2011 and January 2021. EGFR mutations were identified by PCR. ALK rearrangements were identified by immunostaining. Patients without EGFR or ALK mutations were labeled as wild-type (WT). EGFR mutation was detected in 446 (71.02%) patients, ALK rearrangement in 36 (5.73%) patients and WT in 146 (23.25%) patients. EGFR mutations resulted in higher frequency of lung, brain and multiple extrapulmonary metastases than ALK rearrangement. The ALK group exhibited the longest median overall survival (OS), followed by EGFR and WT groups (ALK: 51.60±13.32, EGFR: 24.03±1.22 and WT: 19.63±2.43 months, respectively; P=0.011). In patients with brain metastases, ALK group had a longer median OS than the EGFR group. Because there were few recruited patients with ALK rearrangement, the results were not significant. According to the results of Cox regression model analysis, driver mutations with EGFR and ALK, lower smoking pack-years, younger age, better performance status, no pleural metastasis and fewer extrapulmonary metastases were key prognostic factors. In conclusion, diverse clinical outcomes are driven by different driver mutations. EGFR mutation leads to more extrapulmonary metastases. Median OS was superior in ALK-rearranged NSCLC than EGFR-mutated NSCLC regardless of brain metastases. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

37. Atractylodin Suppresses TGF-β-Mediated Epithelial-Mesenchymal Transition in Alveolar Epithelial Cells and Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice

Author

Chang, Kai-Wei, Zhang, Xiang, Lin, Shih-Chao, Lin, Yu-Chao, Li, Chia-Hsiang, Akhrymuk, Ivan V., Lin, Sheng-Hao, and Lin, Chi-Chien

Subjects
respiratory system, respiratory tract diseases
Abstract

Idiopathic pulmonary fibrosis (IPF) is characterized by fibrotic change in alveolar epithelial cells and leads to the irreversible deterioration of pulmonary function. Transforming growth factor-beta 1 (TGF-β1)-induced epithelial-mesenchymal transition (EMT) in type 2 lung epithelial cells contributes to excessive collagen deposition and plays an important role in IPF. Atractylodin (ATL) is a kind of herbal medicine that has been proven to protect intestinal inflammation and attenuate acute lung injury. Our study aimed to determine whether EMT played a crucial role in the pathogenesis of pulmonary fibrosis and whether EMT can be utilized as a therapeutic target by ATL treatment to mitigate IPF. To address this topic, we took two steps to investigate: 1. Utilization of anin vitro EMT model by treating alveolar epithelial cells (A549 cells) with TGF-β1 followed by ATL treatment for elucidating the underlying pathways, including Smad2/3 hyperphosphorylation, mitogen-activated protein kinase (MAPK) pathway overexpression, Snail and Slug upregulation, and loss of E-cadherin. Utilization of an in vivo lung injury model by treating bleomycin on mice followed by ATL treatment to demonstrate the therapeutic effectiveness, such as, less collagen deposition and lower E-cadherin expression. In conclusion, ATL attenuates TGF-β1-induced EMT in A549 cells and bleomycin-induced pulmonary fibrosis in mice. Published version

Published
2021

38. Performance and Clinical Utility of Various Chronic Obstructive Pulmonary Disease Case-Finding Tools

Author

Chen, Chiung-Zuei, primary, Sheu, Chau-Chyun, additional, Cheng, Shih-Lung, additional, Wang, Hao-Chien, additional, Lin, Meng-Chih, additional, Hsu, Wu-Huei, additional, Lee, Kang-Yun, additional, Perng, Diahn-Warng, additional, Lin, Hen-I, additional, Lin, Ming-Shian, additional, Lin, Sheng-Hao, additional, Tsai, Jong-Rung, additional, Wang, Chin-Chou, additional, Wang, Cheng-Yi, additional, Yang, Tsung-Ming, additional, Liu, Ching-Lung, additional, Wang, Tsai-Yu, additional, and Lin, Ching-Hsiung, additional

Published
2021
Full Text
View/download PDF

39. Subsequent Antituberculous Treatment May Not Be Mandatory Among Surgically Resected Culture-Negative Pulmonary Granulomas: A Retrospective Nationwide Multicenter Cohort Study

Author

Chung, Che-Liang, primary, Huang, Wei-Chang, additional, Huang, Hung-Ling, additional, Chin, Chun-Shih, additional, Cheng, Meng-Hsuan, additional, Lee, Meng-Rui, additional, Lin, Sheng-Hao, additional, Wang, Jann-Yuan, additional, Lin, Ching-Hsiung, additional, Chong, Inn-Wen, additional, Shih, Jin-Yuan, additional, and Yu, Chong-Jen, additional

Published
2021
Full Text
View/download PDF

41. Effectiveness of Nationwide COPD Pay-for-Performance Program on COPD Exacerbations in Taiwan

Author

Cheng, Shih-Lung, primary, Li, Yi-Rong, additional, Huang, Nicole, additional, Yu, Chong-Jen, additional, Wang, Hao-Chien, additional, Lin, Meng-Chih, additional, Chiu, Kuo-Chin, additional, Hsu, Wu-Huei, additional, Chen, Chiung-Zuei, additional, Sheu, Chau-Chyun, additional, Perng, Diahn-Warng, additional, Lin, Sheng-Hao, additional, Yang, Tsung-Ming, additional, Lin, Chih-Bin, additional, Kor, Chew-Teng, additional, and Lin, Ching-Hsiung, additional

Published
2021
Full Text
View/download PDF

44. Effectiveness of Nationwide COPD Pay-for-Performance Program on COPD Exacerbations in Taiwan

Author

Cheng,Shih-Lung, Li,Yi-Rong, Huang,Nicole, Yu,Chong-Jen, Wang,Hao-Chien, Lin,Meng-Chih, Chiu,Kuo-Chin, Hsu,Wu-Huei, Chen,Chiung-Zuei, Sheu,Chau-Chyun, Perng,Diahn-Warng, Lin,Sheng-Hao, Yang,Tsung-Ming, Lin,Chih-Bin, Kor,Chew-Teng, Lin,Ching-Hsiung, Cheng,Shih-Lung, Li,Yi-Rong, Huang,Nicole, Yu,Chong-Jen, Wang,Hao-Chien, Lin,Meng-Chih, Chiu,Kuo-Chin, Hsu,Wu-Huei, Chen,Chiung-Zuei, Sheu,Chau-Chyun, Perng,Diahn-Warng, Lin,Sheng-Hao, Yang,Tsung-Ming, Lin,Chih-Bin, Kor,Chew-Teng, and Lin,Ching-Hsiung

Abstract

Shih-Lung Cheng,1,2,&ast; Yi-Rong Li,3,&ast; Nicole Huang,4 Chong-Jen Yu,5 Hao-Chien Wang,5 Meng-Chih Lin,6 Kuo-Chin Chiu,7 Wu-Huei Hsu,8 Chiung-Zuei Chen,9 Chau-Chyun Sheu,10,11 Diahn-Warng Perng,12 Sheng-Hao Lin,13 Tsung-Ming Yang,14 Chih-Bin Lin,15 Chew-Teng Kor,16 Ching-Hsiung Lin13,17,18 1Department of Internal Medicine, Far Eastern Memorial Hospital, Taipei, 220, Taiwan; 2Department of Chemical Engineering and Materials Science, Yuan Ze University, Zhongli, Taoyuan, 320, Taiwan; 3Changhua Christian Hospital, Thoracic Medicine Research Center, Changhua, 500, Taiwan; 4Institute of Hospital and Health Care Administration, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan; 5Department of Internal Medicine, National Taiwan University Hospital, Taipei, 100, Taiwan; 6Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, 833, Taiwan; 7Division of Chest, Department of Internal Medicine, Poh-Ai Hospital, Luodong, 265, Taiwan; 8Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, 404, Taiwan; 9Division of Pulmonary Medicine, Department of Internal Medicine, National Cheng Kung University, College of Medicine and Hospital, Tainan, 701, Taiwan; 10Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, 807, Taiwan; 11Department of Internal Medicine, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 807, Taiwan; 12Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, 112, Taiwan; 13Department of Internal Medicine, Division of Chest Medicine, Changhua Christian Hospital, Changhua, 500, Taiwan; 14Department of Pulmonary and Critical Care Medicine, Chang Gung Memorial Hospital, Chiayi Branch, 613, Taiwan; 15Department of Internal Medicine

Published
2021

45. Performance and Clinical Utility of Various Chronic Obstructive Pulmonary Disease Case-Finding Tools

Author

Chen,Chiung-Zuei, Sheu,Chau-Chyun, Cheng,Shih-Lung, Wang,Hao-Chien, Lin,Meng-Chih, Hsu,Wu-Huei, Lee,Kang-Yun, Perng,Diahn-Warng, Lin,Hen-I, Lin,Ming-Shian, Lin,Sheng-Hao, Tsai,Jong-Rung, Wang,Chin-Chou, Wang,Cheng-Yi, Yang,Tsung-Ming, Liu,Ching-Lung, Wang,Tsai-Yu, Lin,Ching-Hsiung, Chen,Chiung-Zuei, Sheu,Chau-Chyun, Cheng,Shih-Lung, Wang,Hao-Chien, Lin,Meng-Chih, Hsu,Wu-Huei, Lee,Kang-Yun, Perng,Diahn-Warng, Lin,Hen-I, Lin,Ming-Shian, Lin,Sheng-Hao, Tsai,Jong-Rung, Wang,Chin-Chou, Wang,Cheng-Yi, Yang,Tsung-Ming, Liu,Ching-Lung, Wang,Tsai-Yu, and Lin,Ching-Hsiung

Abstract

Chiung-Zuei Chen,1 Chau-Chyun Sheu,2 Shih-Lung Cheng,3,4 Hao-Chien Wang,5 Meng-Chih Lin,6 Wu-Huei Hsu,7 Kang-Yun Lee,8 Diahn-Warng Perng,9 Hen-I Lin,10 Ming-Shian Lin,11 Sheng-Hao Lin,12 Jong-Rung Tsai,13 Chin-Chou Wang,6 Cheng-Yi Wang,10 Tsung-Ming Yang,14 Ching-Lung Liu,15 Tsai-Yu Wang,16 Ching-Hsiung Lin12,17,18 1Division of Pulmonary Medicine, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; 2Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, 807, Taiwan; 3Department of Internal Medicine, Far Eastern Memorial Hospital, Taipei, 220, Taiwan; 4Department of Chemical Engineering and Materials Science, Yuan Ze University, Zhongli, Taoyuan, 320, Taiwan; 5Department of Internal Medicine, National Taiwan University Hospital, Taipei, 100, Taiwan; 6Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, 404, Taiwan; 7Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, 833, Taiwan; 8Division of Pulmonary Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, 110, Taiwan; 9Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, 112, Taiwan; 10Department of Internal Medicine, Cardinal Tien Hospital, Fu-Jen Catholic University, Taipei, 242, Taiwan; 11Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, 600, Taiwan; 12Division of Chest Medicine, Changhua Christian Hospital, Changhua, 500, Taiwan; 13Division of Respiratory Therapy, College of Medicine, Kaohsiung Medical University, Kaohsiung, 807, Taiwan; 14Department of Pulmonary and Critical Care Medicine, Chang Gung Memorial Hospital, Taoyuan City

Published
2021

46. Novel App-Based Portable Spirometer for the Early Detection of COPD

Author

Lin, Ching-Hsiung, primary, Cheng, Shih-Lung, additional, Wang, Hao-Chien, additional, Hsu, Wu-Huei, additional, Lee, Kang-Yun, additional, Perng, Diahn-Warng, additional, Lin, Hen-I., additional, Lin, Ming-Shian, additional, Tsai, Jong-Rung, additional, Wang, Chin-Chou, additional, Lin, Sheng-Hao, additional, Wang, Cheng-Yi, additional, Chen, Chiung-Zuei, additional, Yang, Tsung-Ming, additional, Liu, Ching-Lung, additional, Wang, Tsai-Yu, additional, and Lin, Meng-Chih, additional

Published
2021
Full Text
View/download PDF

48. Environmental risks and sphingolipid signatures in adult asthma and its phenotypic clusters: a multicentre study

Author

Wu, Chao-Chien, Wang, Chin-Chou, Chung, Wen-Yu, Sheu, Chau-Chyun, Yang, Yi-Hsin, Cheng, Ming-Yen, Lai, Ruay-Sheng, Leung, Sum-Yee, Lin, Chi-Cheng, Wei, Yu-Feng, Lin, Ching-Hsiung, Lin, Sheng-Hao, Hsu, Jeng-Yuan, Huang, Wei-Chang, Tseng, Chia-Cheng, Lai, Yung-Fa, Cheng, Meng-Hsuan, Chen, Huang-Chi, Yang, Chih-Jen, Hsu, Shih-Chang, Su, Chian-Heng, Wang, Chien-Jen, Liu, Huei-Ju, Chen, Hua-Ling, Hsu, Yuan-Ting, Hung, Chih-Hsing, Lee, Chon-Lin, Huang, Ming-Shyan, and Huang, Shau-Ku

Abstract

BackgroundAdult asthma is phenotypically heterogeneous with unclear aetiology. We aimed to evaluate the potential contribution of environmental exposure and its ensuing response to asthma and its heterogeneity.MethodsEnvironmental risk was evaluated by assessing the records of National Health Insurance Research Database (NHIRD) and residence-based air pollution (particulate matter with diameter less than 2.5 micrometers (PM2.5) and PM2.5-bound polycyclic aromatic hydrocarbons (PAHs)), integrating biomonitoring analysis of environmental pollutants, inflammatory markers and sphingolipid metabolites in case–control populations with mass spectrometry and ELISA. Phenotypic clustering was evaluated by t-distributed stochastic neighbor embedding (t-SNE) integrating 18 clinical and demographic variables.FindingsIn the NHIRD dataset, modest increase in the relative risk with time-lag effect for emergency (N=209 837) and outpatient visits (N=638 538) was observed with increasing levels of PM2.5and PAHs. Biomonitoring analysis revealed a panel of metals and organic pollutants, particularly metal Ni and PAH, posing a significant risk for current asthma (ORs=1.28–3.48) and its severity, correlating with the level of oxidative stress markers, notably Nε-(hexanoyl)-lysine (r=0.108–0.311, p<0.05), but not with the accumulated levels of PM2.5exposure. Further, levels of circulating sphingosine-1-phosphate and ceramide-1-phosphate were found to discriminate asthma (p<0.001 and p<0.05, respectively), correlating with the levels of PAH (r=0.196, p<0.01) and metal exposure (r=0.202–0.323, p<0.05), respectively, and both correlating with circulating inflammatory markers (r=0.186–0.427, p<0.01). Analysis of six phenotypic clusters and those cases with comorbid type 2 diabetes mellitus (T2DM) revealed cluster-selective environmental risks and biosignatures.InterpretationThese results suggest the potential contribution of environmental factors from multiple sources, their ensuing oxidative stress and sphingolipid remodeling to adult asthma and its phenotypic heterogeneity.

Published
2023
Full Text
View/download PDF

49. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Author

Goldman, Jonathan W, primary, Dvorkin, Mikhail, additional, Chen, Yuanbin, additional, Reinmuth, Niels, additional, Hotta, Katsuyuki, additional, Trukhin, Dmytro, additional, Statsenko, Galina, additional, Hochmair, Maximilian J, additional, Özgüroğlu, Mustafa, additional, Ji, Jun Ho, additional, Garassino, Marina Chiara, additional, Voitko, Oleksandr, additional, Poltoratskiy, Artem, additional, Ponce, Santiago, additional, Verderame, Francesco, additional, Havel, Libor, additional, Bondarenko, Igor, additional, Każarnowicz, Andrzej, additional, Losonczy, György, additional, Conev, Nikolay V, additional, Armstrong, Jon, additional, Byrne, Natalie, additional, Thiyagarajah, Piruntha, additional, Jiang, Haiyi, additional, Paz-Ares, Luis, additional, Voitko, Nataliia, additional, Kazarnowicz, Andrzej, additional, Özgüroglu, Mustafa, additional, Conev, Nikolay, additional, Hochmair, Maximilian, additional, Burghuber, Otto, additional, Çiçin, Irfan, additional, Moiseenko, Vladimir, additional, Erman, Mustafa, additional, Kowalski, Dariusz, additional, Wojtukiewicz, Marek, additional, Adamchuk, Hryhoriy, additional, Vasilyev, Alexander, additional, Shevnia, Serhii, additional, Valev, Spartak, additional, Insa Molla, Maria Amelia, additional, Ursol, Grygorii, additional, Chiang, Anne, additional, Hartl, Sylvia, additional, Horváth, Zsolt, additional, Pajkos, Gábor, additional, Kim, Sang-We, additional, Smolin, Alexey, additional, Göksel, Tuncay, additional, Dakhil, Shaker, additional, Roubec, Jaromir, additional, Bogos, Krisztina, additional, Cornelissen, Robin, additional, Lee, Jong-Seok, additional, Garcia Campelo, Maria Rosario, additional, Lopez Brea, Marta, additional, Alacacioglu, Ahmet, additional, Casarini, Ignacio, additional, Ilieva, Rumyana, additional, Tonev, Ivan, additional, Somfay, Attila, additional, Bar, Jair, additional, Zer Kuch, Alona, additional, Minelli, Mauro, additional, Bartolucci, Roberta, additional, Roila, Fausto, additional, Saito, Haruhiro, additional, Azuma, Koichi, additional, Lee, Gyeong-Won, additional, Luft, Alexander, additional, Urda, Michal, additional, Delgado Mingorance, Juan Ignacio, additional, Majem Tarruella, Margarita, additional, Spigel, David, additional, Koynov, Krassimir, additional, Zemanova, Milada, additional, Panse, Jens, additional, Schulz, Christian, additional, Pápai Székely, Zsolt, additional, Sárosi, Veronika, additional, Delmonte, Angelo, additional, Bettini, Anna Cecilia, additional, Nishio, Makoto, additional, Okamoto, Isamu, additional, Hendriks, Lizza, additional, Mandziuk, Slawomir, additional, Lee, Yun Gyoo, additional, Vladimirova, Lyubov, additional, Isla Casado, Dolores, additional, Domine Gomez, Manuel, additional, Navarro Mendivil, Alejandro, additional, Morán Bueno, Teresa, additional, Wu, Shang-Yin, additional, Knoble, Jeanna, additional, Skrickova, Jana, additional, Venkova, Violetka, additional, Hilgers, Werner, additional, Laack, Eckart, additional, Bischoff, Helge, additional, Fülöp, Andrea, additional, Laczó, Ibolya, additional, Kósa, Judit, additional, Telekes, András, additional, Yoshida, Tatsuya, additional, Kanda, Shintaro, additional, Hida, Toyoaki, additional, Hayashi, Hidetoshi, additional, Maeda, Tadashi, additional, Kawamura, Tetsuji, additional, Nakahara, Yasuharu, additional, Claessens, Niels, additional, Lee, Ki Hyeong, additional, Chiu, Chao-Hua, additional, Lin, Sheng-Hao, additional, Li, Chien-Te, additional, Demirkazik, Ahmet, additional, Schaefer, Eric, additional, Nikolinakos, Petros, additional, Schneider, Jeffrey, additional, Babu, Sunil, additional, Lamprecht, Bernd, additional, Studnicka, Michael, additional, Fausto Nino Gorini, Carlos, additional, Kultan, Juraj, additional, Kolek, Vitezslav, additional, Souquet, Pierre-Jean, additional, Moro-Sibilot, Denis, additional, Gottfried, Maya, additional, Smit, Egbert, additional, Lee, Kyung Hee, additional, Kasan, Peter, additional, Chovanec, Jozef, additional, Goloborodko, Olexandr, additional, Kolesnik, Oleksii, additional, Ostapenko, Yuriy, additional, Lakhanpal, Shailendra, additional, Haque, Basir, additional, Chua, Winston, additional, Stilwill, Joseph, additional, Sena, Susana Noemi, additional, Girotto, Gustavo Colagiovanni, additional, De Marchi, Pedro Rafael Martins, additional, Martinelli de Oliveira, Fabricio Augusto, additional, Dos Reis, Pedro, additional, Krasteva, Rositsa, additional, Zhao, Yanqiu, additional, Chen, Chengshui, additional, Koubkova, Leona, additional, Robinet, Gilles, additional, Chouaid, Christos, additional, Grohe, Christian, additional, Alt, Jürgen, additional, Csánky, Eszter, additional, Somogyiné Ezer, Éva, additional, Heching, Norman Isaac, additional, Kim, Young Hak, additional, Aatagi, Shinji, additional, Kuyama, Shoichi, additional, Harada, Daijiro, additional, Nogami, Naoyuki, additional, Nokihara, Hiroshi, additional, Goto, Hisatsugu, additional, Staal van den Brekel, Agnes, additional, Cho, Eun Kyung, additional, Kim, Joo-Hang, additional, Ganea, Doina, additional, Ciuleanu, Tudor, additional, Popova, Ekaterina, additional, Sakaeva, Dina, additional, Stresko, Marian, additional, Demo, Pavol, additional, Godal, Robert, additional, Wei, Yu-Feng, additional, Chen, Yen-Hsun, additional, Hsia, Te-Chun, additional, Lee, Kang-Yun, additional, Chang, Huang-Chih, additional, Wang, Chin-Chou, additional, Dowlati, Afshin, additional, Sumey, Christopher, additional, Powell, Steven, additional, Goldman, Jonathan, additional, Zarba, Juan Jose, additional, Batagelj, Emilio, additional, Pastor, Andrea Viviana, additional, Zukin, Mauro, additional, Baldotto, Clarissa Serodio da Rocha, additional, Schlittler, Luis Alberto, additional, Calabrich, Aknar, additional, Sette, Claudia, additional, Dudov, Asen, additional, Zhou, Caicun, additional, Lena, Hervé, additional, Lang, Susanne, additional, Pápai, Zsuzsanna, additional, Goto, Koichi, additional, Umemura, Shigeki, additional, Kanazawa, Kenya, additional, Hara, Yu, additional, Shinoda, Masahiro, additional, Morise, Masahiro, additional, Hiltermann, Jeroen, additional, Mróz, Robert, additional, Ungureanu, Andrei, additional, Andrasina, Igor, additional, Chang, Gee-Chen, additional, Vynnychenko, Ihor, additional, Shparyk, Yaroslav, additional, Kryzhanivska, Anna, additional, Ross, Helen, additional, Mi, Kailhong, additional, Jamil, Rodney, additional, Williamson, Michael, additional, Spahr, Joseph, additional, Han, Zhigang, additional, Wang, Mengzhao, additional, Yang, Zhixiong, additional, Hu, Jie, additional, Li, Wei, additional, Zhao, Jun, additional, Feng, Jifeng, additional, Ma, Shenglin, additional, Zhou, Xiangdong, additional, Liang, Zongan, additional, Hu, Yi, additional, Chen, Yuan, additional, Bi, Minghong, additional, Shu, Yongqian, additional, Nan, Kejun, additional, Zhou, Jianying, additional, Zhang, Wei, additional, Ma, Rui, additional, Yang, Nong, additional, Lin, Zhong, additional, Wu, Gang, additional, Fang, Jian, additional, Zhang, Helong, additional, Wang, Kai, additional, and Chen, Zhendong, additional

Published
2021
Full Text
View/download PDF

50. Environmental Risks and Sphingolipid Signatures in Adult Asthma and Its Phenotypic Clusters: A Multi-Center Exploratory Study

Author

Wu, Chao-Chien, primary, Wang, Chin-Chou, additional, Chung, Wen-Yu, additional, Sheu, Chau-Chyun, additional, Yang, Yi-Hsin, additional, Cheng, Ming-Yen, additional, Lai, Ruay-Sheng, additional, Leung, Sum-Yee, additional, Lin, Chi-Cheng, additional, Wei, Yu-Feng, additional, Lin, Ching-Hsiung, additional, Lin, Sheng-Hao, additional, Hsu, Jeng-Yuan, additional, Huang, Wei-Chang, additional, Zheng, Jia-Cheng, additional, Lai, Yung-Fa, additional, Cheng, Meng-Hsuan, additional, Chen, Huang-Chi, additional, Yang, Zhi-Ren, additional, Hsu, Shih-Chang, additional, Su, Chian-Heng, additional, Wang, Chien-Jen, additional, Liu, Huei-Ju, additional, Chen, Hua-Ling, additional, Hsu, Yuan-Ting, additional, Hung, Chih-Hsing, additional, Lee, Chon-Lin, additional, Huang, Ming-Shyan, additional, Huang, Shau-Ku, additional, and Study, The Consortium for Taiwan Asthma, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results